Dr. Balis's research focuses on the clinical pharmacology of anticancer drugs, new drug development, and clinical trial design and endpoints. He studies the pharmacokinetics and pharmacodynamics of anticancer drugs and has applied pharmacological principles to clinical trial design and clinical drug development. He is developing new biomarkers to serve as surrogate endpoints of drug toxicity or efficacy in clinical trials.
Oncogenes such as MYC are notorious troublemakers that promote cancer. Previous research strategies have focused on finding ways to quiet down levels of MYC; however, basic scientists at Children’s Hospital of Philadelphia took the opposite approach.
Physician-scientists in the Cancer Center at Children's Hospital of Philadelphia (CHOP) have developed a preclinical, potent therapy attached to an antibody that targets a surface protein expressed in most childhood neuroblastomas, effectively killing cancer cells.
From cancer drugs designed to match a child's specific molecular abnormality, to a phone app that can offer a dermatologic diagnosis quicker than an office visit, the future of children's healthcare is unfolding right before our eyes at the Children's Hospital of Philadelphia Research Institute.
Researchers from the Children's Oncology Group (COG) have developed a new standardized dosing method for anticancer drugs in infants to use across all COG clinical trials. This unified method, based on dose banding and organized into tables for different drugs and dose levels, will address the limitations and variability that researchers can encounter in current methods.